



شبكة المعلومات الجامعية

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ





شبكة المعلومات الجامعية



شبكة المعلومات الجامعية

التوثيق الالكتروني والميكرو فيلم

جامعة عين شمس

التوثيق الالكتروني والميكروفيلم

قسم

نقسم بلله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأفلام قد اعدت دون أية تغيرات



يجب أن

تحفظ هذه الأفلام بعيداً عن الغبار

في درجة حرارة من 15 – 20 مئوية ورطوبة نسبية من 20-40 %

To be kept away from dust in dry cool place of
15 – 25c and relative humidity 20-40 %



شبكة المعلومات الجامعية



بعض الوثائق الأصلية تالفة



شبكة المعلومات الجامعية




بالرسالة صفحات

لم ترد بالأصل

B 1917

*I dedicate this
work to my
family*



2000

ACKNOWLEDGEMENT

For whom no words of thanks and feelings are sufficient. I would like to express my profound gratitude to prof. **Dr. Mostafa. Aboul Enein**, Professor of clinical Pathology, NCI, Cairo University, who offered me without any limitation and gave me much of his valuable time. I have the honor to present this study under his supervision.

I'm greatly indebted to prof. **Dr. mahmoud H. Fawzy ELGuibaly**, professor of clinical pathology, NCI, Cairo University for his cooperative attitude.

I sincerely thank **Dr. Lobna Abdel Azeem Refaat**, Assistant Professor of clinical pathology, NCI, Cairo University, for her helpful role, excellent advice and guidance.

My profound thanks to **Dr. Khaled Mostafa Aboul Enein**, Assistant professor of Clinical pathology, NCI, Cairo University, for his patience and help throught the practical work of this study.

I would also like to express my gratitude to prof. **Dr. Hussein Gaballah**, Lecturer of medical oncology, NCI, Cairo University, for his assistance.

I'm grateful to prof. **Dr. Enas El Atar**, professor of biostatistics and head of the department for her great contribution in biostatistical analysis of this study.



LIST OF CONTENTS

INTRODUCTION AND AIM OF WORK.....	1
REVIEW OF LITERATUR.....	3
Cancer breast.....	3
Normal haemostasis.....	16
The endothelium.....	37
Major components involved in endothelial damage.....	50
PATIENTS AND METHODS.....	75
RESULTS.....	95
DISCUSSION.....	119
SUMMARY AND CONCLUSION.....	129
REFERENCES.....	133
ARABIC SUMMARY	

List of abbreviations

13-HoDE:	13- Hydroxy –octadecadienoic acid
APC:	Activated protein C
ADP :	Adenosine diphosphate
ATIII:	Antithrombin III
ATP:	Adenosine Triphosphate
BSA:	Bovine serum Albumin
C4b:	Complement component 4b binding protein
Ca ²⁺ :	Calcium ions
C-AMP:	cyclic adenosine monophosphate
CT:	computerized tomography
DCI:	ductal carcinoma in situ
DIC:	disseminated intravascular coagulation
ECs:	Endothelial cells.
EDCF:	Endothelial derived contracting factor
EDRF:	Endothelial derived releasing factor
EGF:	epidermal growth factor
ELISA:	Enzyme- linked immunosorbent assay
FDP:	fibrin degradation products
FSP:	fibrin split products
Gp:	glycoprotein
HC.II:	heparin co-factor II
HMWK:	High molecular weight kininogen
HRP:	horse radish peroxidase
ICAM:	intracellular adhesion molecule

List of tables

Table (1):	Incidence of breast cancer with age	3
Table (2):	follow-up studies of breast cancer & incidence after radiotherapy for lymphoma	4
Table (3):	Risk of breast cancer after multiple diagnostic x-rays.....	4
Table (4):	Presenting symptoms in 1205 patients with operable breast cancer.	7
Table (5):	Traditional prognostic parameters for human mammary carcinoma.	12
Table (6):	Inhibitory affect of serine –protease inhibitors	34
Table (7):	Summary of endothelial cells mediators.....	49
Table (8):	A revised classification of vWD.....	66
Table (9):	Clinicopathological data and biochemical findings of early breast cancer cases.....	100
Table (10):	Clinicopathological data and biochemical findings of metastatic breast cancer cases	101
Table (11):	Control normal levels of T.M. vWF, PGI2.....	102
Table (12):	T.M levels in early breast cancer as compared to normal control	103
Table (13):	T.M levels in metastatic breast cancer as compared to normal control.....	104
Table (14):	Comparative analysis of mean of T.M levels between control, early and metastatic breast cancer cases....	105

IDC:	invasive duct carcinoma
Ig:	immunoglobulin
KDa:	Kilodalton
LACI:	Lipid –associated coagulation inhibitor
O.D:	Optical density
OCS:	open canalicular system
PAF:	Platelet activating factor
PAI:	plasminogen activator- inhibitor
PC:	Protein C
PCI:	protein C inhibitor
PDGF:	platelet derived growth factor
PECAM:	platelet- Endothelial cell adhesion molecule
PF3:	platelet factor 3
PG:	prostaglandin
PGI ₂ :	prostacyclin
PLA ₂ :	phospholipase A ₂
PNBB:	para nitrophenyl phosphate
SLE:	systemic lupus erythromatosis
TF:	tissue factor
TM:	thrombomodulin
TMP:	tetramethylbenzidine
TNF:	tumor necrosis factor
T-PA:	Tissue- type plasminogen activator
Tx:	Thromboxane
u-PA:	Urokinase- plasminogen activator
VCAM:	vascular cell adhesion molecule
vWD:	von Willebrand disease
vWF: AgII:	von Willebrand factor: Antigen II
vWF:	von Willebrand factor

List of figures

Fig (1):	Diagrammatic representation of the ultrastructure of platelets	17
Fig (2):	Synthesis of prostaglandins in platelet and Endothelial cells during plug formation	24
Fig (3):	the cascade theory of coagulation	26
Fig (4):	the fibrinolytic system	30
Fig (5):	plasmin action on fibrinogen	31
Fig (6):	Activation of protein C system	35
Fig (7):	Hemostatic properties of Endothelium	38
Fig (8):	structural domain of human T.M	54
Fig (9):	A- vWF structural and binding domains	59
	B- vWF multimerization	
Fig(10, 11):	The Arachidonate cascade	68,69
Fig (12):	Reference calibration curve of T.M.	92
Fig (13)	Reference calibration curve of V.W.F	93
Fig (14)	Reference calibration curve PGI2	94
Fig (15):	comparative analysis of mean of T.M levels between control, early and metastatic breast cancer cases	113
Fig (16):	comparative analysis of mean of vWF levels between control, early and metastatic breast cancer cases	114
Fig (17):	comparative analysis of mean of PGI2 levels between control/ early and metastatic breast cancer cases	115
Fig (18):	correlation between T.M and v.W.F.	116
Fig (19):	correlation between T.M and PGI2	117
Fig (20):	correlation between PGI2 and vWF	118

Table (15):	v.W.F levels in early breast cancer as compared to normal controls.....	106
Table (16):	v.W.F levels in metastatic breast cancer as compared to normal control.	107
Table (17):	comparative analysis of mean of vWF levels between control, early and metastatic breast cancer cases....	108
Table (18):	PGI2 levels in early breast cancer as compared to normal control	109
Table (19):	PGI2 levels in metastatic breast cancer as compared to normal control	110
Table (20):	Comparative analysis of mean of PGI2 levels between control, early and metastatic breast cancer cases.....	111
Table (21):	Correlation of the 3 different biochemical parameters studied in breast cancer cases	112
Table (22):	Correlation of the 3 different biochemical parameters in metastatic breast cancer group in relation to number of metastatic site.	112